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ABSTRACT
Objectives  Adult-acquired ﬂ  at foot secondary to a 
dysfunctional posterior tibialis tendon (PTT) is often 
treated by surgical transfer of the ﬂ  exor digitorum longus 
tendon (FDLT). In this study, the authors compared 
normal PTT, stage II dysfunctional PTT and replacement 
FDLT, aiming to deﬁ  ne changes in collagen modiﬁ  cation, 
glycosaminoglycan (GAG) and the expression of matrix 
and metalloproteinase mRNA.
Methods  Normal PTTs were obtained from patients with 
no history of tendon problems. Samples of dysfunctional 
PTT and replacement FDLT tissue were obtained from 
patients undergoing surgical reconstruction. Tissue 
samples were analysed for total collagen and GAG, 
pentosidine and collagen cross-links. Total RNA was 
assayed for mRNA encoding matrix proteins and 
metalloproteinases, using real-time reverse transcription 
PCR. Differences between clinical groups were assessed 
using non-parametric statistics.
Results  Dysfunctional PTT contained higher levels of 
GAG and lower levels of pentosidine than normal PTT 
or FDLT. In contrast, collagen in FDLT contained fewer 
ketoimine and more aldimine cross-links than either 
normal or dysfunctional PTT. mRNA encoding types I and 
III collagens, aggrecan, biglycan, matrix metalloproteinase 
(MMP)-2, -13 and -23, and a disintegrin and 
metalloproteinase (ADAM)-12L each showed increased 
levels in dysfunctional PTT compared with either normal 
PTT or (except MMP-13) FDLT. In contrast, MMP-3 and 
ADAM with thrombospondin domain (ADAMTS)-5 mRNA 
were lower in both dysfunctional PTT and FDLT than 
in normal PTT, while ADAMTS-1 mRNA was lower in 
dysfunctional PTT than in FDLT.
Conclusions  Stage II dysfunctional PTT shows 
biochemical and molecular changes consistent with a 
chronic remodelling of the extracellular matrix, rather than 
rupture, while the replacement FDLT resembles normal 
PTT in many, but not all, parameters.
INTRODUCTION
Dysfunction of the human posterior tibialis ten-
don (PTT) is a common cause of adult-acquired ﬂ  at 
foot. PTT disease particularly affects middle-aged 
women and causes a signiﬁ  cant proportion of the 
tendon pathology seen in the clinic.1–5 In stage II 
dysfunction, in which the foot retains ﬂ  exibility 
and the defect is correctible, the PTT is elongated 
and shows marked degeneration, but is not gener-
ally ruptured.2–5 The preferred surgical treatment 
involves tendon transfer to restore functional sup-
port of the foot arch, normally using the neighbour-
ing ﬂ  exor digitorum longus tendon (FDLT), with a 
calcaneal osteotomy to enhance biomechanical 
performance.2 5–7
The extracellular matrix of tendons varies 
between different tendons and regionally within 
tendons, and there are changes in tendinopathy 
or ruptured tendons compared with normal ten-
dons.8 9 There is a linear, age-dependent accumu-
lation of collagen modiﬁ  cations in human biceps 
brachii and patellar tendons that indicates a low 
rate of turnover of the matrix.10–12 The absence 
of an equivalent accumulation of modiﬁ  cations in 
supraspinatus tendons is consistent with a higher 
level of collagen replacement in these injury-prone 
tendons.10 A difference in collagen turnover rates 
has also been described recently in equine com-
mon digital extensor and superﬁ  cial digital ﬂ  exor 
tendons.13 In normal tendons, versican is the pre-
dominant large aggregating proteoglycan in the 
tensile mid-tendon, but aggrecan, which is charac-
teristic of cartilage, is present in ﬁ  brocartilaginous 
regions where the tendons attach to bone or wrap 
around pivots.14 15 In chronic Achilles tendinopa-
thy, increased glycosaminoglycan (GAG) levels in 
the morphologically abnormal mid-tendon indicate 
increased proteoglycan,16 and high levels of mRNA 
encoding aggrecan and biglycan are expressed.17 
The observed differences in matrix protein com-
position may also involve changed expression and/
or activity of many enzymes of the metalloprotei-
nase clan.18 19
In the normal PTT, as in other tendons, ﬁ  bro-
cartilaginous regions enriched in aggrecan and 
type II collagen are found at the entheses and 
on the inner zone of the tendon where it wraps 
around the medial malleolus.20 21 In stage II PTT 
dysfunction, hypercellularity, increased vascu-
larisation, increased mucin levels and a disrupted 
collagen matrix containing a higher proportion of 
types III and V collagens have been reported.22–24 
Otherwise, however, little is known of the detailed 
biochemical and molecular changes underlying 
PTT dysfunction. In this study, we aimed to deter-
mine how biochemical markers of matrix com-
position, and the expression of mRNA encoding 
a range of matrix components and metalloprotei-
nases, shown previously to change signiﬁ  cantly in 
other tendinopathies,17  19 varied between normal 
and stage II dysfunctional PTT. Given that the PTT 
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Histological and biochemical characterisation, isolation of total 
RNA, and analysis by relative quantitative PCR
See online supplementary text for a description of these 
methods.
Statistical analysis
Differences between clinical groups are described as n-fold dif-
ferences between the medians and were analysed using either 
the Mann–Whitney U test or, for the paired samples of dysfunc-
tional PTT and FDLT, the Wilcoxon signed rank test.
RESULTS
Biochemical analysis of PTT and FDLT from female patients
Tendon collagen and proteoglycan content
The median collagen content of normal PTT, dysfunctional PTT 
and FDLT samples from female patients showed no signiﬁ  cant 
differences (table 2). In contrast, signiﬁ  cant differences in pro-
teoglycan content were observed: dysfunctional PTT contained 
twofold and sixfold higher levels of GAG than normal PTT and 
FDLT, respectively. The threefold higher level of GAG in normal 
PTT compared with FDLT was also signiﬁ  cant (table 2).
Pentosidine modiﬁ  cation and cross-linking of collagen
Normal PTT showed a linear increase in pentosidine (non-enzy-
matic glycation of collagen) with increasing age of the donor, and 
FDLT generally showed a similar pentosidine content to normal 
and FDLT are functionally different tendons, and may therefore 
have different composition (see Discussion), we also assayed 
the same parameters in the FDLT used for reconstruction.
METHODS
Tendon specimens
Consistent with PTT dysfunction occurring more widely in 
women, the majority of patients presenting in this study were 
female (table 1). Samples of PTT and FDLT tissue were obtained 
from patients clinically staged as having stage II PTT dysfunc-
tion and being surgically treated with FDLT transfer. Specimens 
of normal PTT were obtained from patients with no history 
of tendon problems, either undergoing lower limb amputa-
tion for bone tumours (Royal National Orthopaedic Hospital, 
Stanmore) or with foot drop (usually resulting from a slipped 
intervertebral disc) being corrected by the transfer of normal 
PTT (Addenbrooke’s Hospital, Cambridge). Procedures were 
approved by the relevant local research ethics committees, and 
written consent was obtained from informed patients.
Specimens of normal PTT and FDLT generally showed nor-
mal tendon organisation, whereas specimens from patients 
with stage II PTT dysfunction showed features typical of ten-
dinopathy (table 1).16 22 24 25 Although morphologically normal, 
we could not exclude the possibility that the phenotype of the 
normal PTT may have been affected by reduced weight-bearing 
and mobility, and/or chemotherapy.
Table 2  Collagen content, GAG content and collagen modiﬁ  cations in normal PTT, stage II PTT and FDLT from female patients
Median (range) p Value
  Normal PTT Stage II PTT FDLT N PTT v StII PTT N PTT v FDLT StII PTT v FDLT
Collagen and GAG (µg/mg dry weight)
  Collagen 649 (455–819) 535 (113–1275) 735 (133–1000) nsd nsd nsd
  GAG 6.5 (5.0–15.6) 13.5 (4.8–31.5) 2.2 (0.8–13.2) p<0.05 p<0.001 p<0.001
Collagen modiﬁ  cations (mol/mol collagen)
 Pentosidine 4.2×10−3 (2.1–7.4) 1.6×10−3 (0.3–4.2) 5.8×10−3 (3.3–10.8) p<0.05 nsd p<0.001
  OHPyr 0.48 (0.26–0.59) 0.38 (0.27–0.50) 0.13 (0.05–0.24) nsd p<0.001 p<0.001
  HLKNL 0.30 (0.12–0.59) 0.26 (0.14–0.77) 0.27 (0.15–0.46) nsd nsd nsd
  HHL 0.11 (0.09–0.14) 0.11 (0.06–0.16) 0.20 (0.16–0.26) nsd p<0.001 p<0.001
 HLNL 0.10 (0.06–0.17) 0.11 (0.05–0.16) 0.22 (0.11–0.33) nsd p<0.001 p<0.001
FDLT, ﬂ  exor digitorum longus tendon; GAG, glycosaminoglycan; N, normal; nsd, no signiﬁ  cant difference; PTT, posterior tibialis tendon; StII, stage II. OHPyr, hydroxylysyl pyridinoline, 
HLKNL, hydroxylysino-5-ketonorleucine, HHL, histidinohydroxylysinonorleucine, HLNL, hydroxylysinonorleucine
Table 1  Normal PTT, stage II PTT and FDLT samples
Women Men
  Normal PTT Stage II PTT FDLT Normal PTT Stage II PTT FDLT
Number of samples 6 25* 25* 7 7 6
Age (years), median (range) 53.5 (29–87) 60 (30–77) 60 (30–77) 54 (35–63) 55 (19–72) 56.5 (54–72)
Histology
 Normal 5† 1 19† 5 1 5
 Abnormal 0 24 5 2 6 1
Abnormal features
 Fibre  disorganisation 0 24 0 0 6 0
 Increased  cellularity 0 21 4 1 6 0
 Cell  rounding 0 24 3 2 6 1
 Increased  GAG 0 24 0 0 6 0
  Blood vessel inﬁ  ltration 0 24 5 1 6 0
Tendon samples were collected from patients as described in the text. Dissected pieces were ﬁ  xed and examined histologically 
using standard techniques (see online supplementary text).
*The 25 samples of stage II PTT and FDLT are paired samples from the same individual female patients. 
†Indicates that one each of these sample sets was not available for histology. Five abnormal features were scored: collagen 
ﬁ  bre disorganisation, increased cellularity, cell rounding, increased GAG content and blood vessel inﬁ  ltration (indicating 
neovascularisation or angiogenesis). The number of samples presenting normal and abnormal appearance is shown, together 
with the numbers of samples showing each speciﬁ  c abnormality.
FDLT, ﬂ  exor digitorum longus tendon; GAG, glycosaminoglycan; PTT, posterior tibialis tendon.
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PTT of equivalent age (ﬁ  gure 1A). In contrast, dysfunctional PTT 
collagen contained signiﬁ  cantly lower levels of pentosidine than 
that predicted by age from normal PTT or paired FDLT samples 
(ﬁ  gure 1A, table 2).
When the pattern of collagen cross-linking was considered, 
FDLT differed markedly from both normal and dysfunctional 
PTT (table 2). Ketoimine cross-link levels were lower in FDLT 
than in either normal or dysfunctional PTT; this was due to 
differences in hydroxylysyl pyridinoline (OHPyr) levels, not in 
hydroxylysino-5-ketonorleucine (HLKNL) (table 2), and applied 
across the age range (ﬁ  gure 1B). In contrast, aldimine cross-link 
levels were higher in FDLT than in either the normal or dysfunc-
tional PTT, and this was due to differences in both histidino-
hydroxylysinonorleucine (HHL) and hydroxylysinonorleucine 
(HLNL) levels (table 2). Similarly to the results for the pentosi-
dine modiﬁ  cation, OHPyr levels in normal PTT showed some 
increase with age, and samples of dysfunctional PTT contained 
lower levels of OHPyr than predicted by age from normal PTT 
(ﬁ  gure 1B).
mRNA expression in PTT and FDLT from female patients
Of the mRNA assayed, only matrix metalloproteinase (MMP)-2 
mRNA showed a signiﬁ  cant change with increasing age, a small 
increase in normal PTT (data not shown); however, this could 
not account for the difference observed between normal and 
dysfunctional PTT (see below).
mRNA encoding collagens and proteoglycans
mRNA of each of the major extracellular matrix proteins was 
readily detected in all samples of PTT and FDLT (table 3, ﬁ  gures 
2 and 3). mRNA of the small leucine-rich proteoglycan, decorin, 
was expressed at the highest levels (~10−3 relative to 18S rRNA), 
and showed no signiﬁ  cant differences between the three clinical 
groups (ﬁ  gure 2A). mRNA of the large aggregating proteoglycan, 
versican, also showed no difference between normal and dys-
functional PTT, but showed 60% higher expression in dysfunc-
tional PTT than in FDLT (ﬁ  gure 2C). Types I and III collagens 
(α1 chains), aggrecan and biglycan each showed between 
threefold and 10-fold higher mRNA expression in dysfunc-
tional PTT than in either normal PTT or FDLT, which were 
not signiﬁ  cantly different from each other (table 3; ﬁ  gures 2B 
and 3A).
Figure 1  Accumulation of pentosidine and hydroxylysyl pyridinoline 
cross-links in collagen in female posterior tibialis tendon (PTT) and 
ﬂ  exor digitorum longus tendon (FDLT) as a function of age. (A) 
Pentosidine and (B) OHPyr cross-links were determined by HPLC as 
outlined in the text, and plotted against the age of the donor. Each 
point represents an individual sample. The broken line shows linear 
regression analysis based on the normal PTT samples: (A) R2=0.92, 
p=0.01; (B) R2=0.85, p=0.02.
Table 3  mRNA expression in normal PTT, stage II PTT and FDLT from female patients
mRNA/18S p Value
Gene Normal PTT Stage II PTT FDLT N PTT v StII PTT N PTT v FDLT StII PTT v FDLT
Type I collagen 7.6×10−05 72.0×10−05 20.6×10−05 p<0.001 nsd p<0.001
Type III collagen 3.8×10−05 24.4×10−05 9.0×10−05 p<0.01 nsd p<0.05
Aggrecan 5.3×10−06 28.3×10−06 4.8×10−06 p=0.01 nsd p<0.001
Versican 1.9×10−05 1.6×10−05 0.9×10−05 nsd nsd p<0.01
Biglycan 4.7×10−05 20.8×10−05 4.7×10−05 p<0.05 nsd p<0.001
Decorin 1.4×10−03 0.8×10−03 0.6×10−03 nsd nsd nsd
MMP-1 5.8×10−09 (<2×10−09)* (<2×10−09)* nsd nsd nsd
MMP-2 1.3×10−05 5.5×10−05 1.5×10−05 p<0.01 nsd p<0.01
MMP-3 1.7×10−05 0.1×10−05 0.1×10−05 p=0.01 p<0.01 nsd
MMP-13 (<2×10−09)* 41.6×10−09 8.8×10−09 p<0.05 nsd nsd
MMP-23 2.0×10−08 33.4×10−08 15.0×10−08 p<0.05 nsd p<0.01
ADAM-12L 4.6×10−08 73.5×10−08 40.7×10−08 p=0.01 nsd p<0.01
ADAMTS-1 1.8×10−06 0.9×10−06 2.6×10−06 nsd nsd p<0.001
ADAMTS-4 2.8×10−07 4.8×10−07 4.1×10−07 nsd nsd p<0.01
ADAMTS-5 2.3×10−06 0.9×10−06 0.9×10−06 p=0.001 p<0.01 nsd
Tendon RNA samples were assayed for speciﬁ  c mRNA, relative to 18S rRNA as described in the text, and the median value for each group is shown.
*Indicates that this mRNA was below the detection limit in the majority of the samples in this group.
ADAM, a disintegrin and metalloproteinase; ADAMTS, ADAM with thrombospondin domain; FDLT, ﬂ  exor digitorum longus tendon; MMP, matrix metalloproteinase; N, normal; nsd, no 
signiﬁ  cant difference; PTT, posterior tibialis tendon; StII, stage II.
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mRNA encoding metalloproteinases
In normal PTT, MMP-2 and MMP-3 were the most highly 
expressed of the metalloproteinase mRNAs, while mRNA levels 
of the collagenases, MMP-1 and MMP-13, were low or unde-
tectable (table 3). The expression of mRNA of MMP-2, MMP-23 
and a disintegrin and metalloproteinase (ADAM)-12L were each 
increased between fourfold and 16-fold in dysfunctional PTT 
compared with normal PTT, and there was detectable expres-
sion of MMP-13 in most dysfunctional PTT (table 3; ﬁ  gures 2D 
and 3B). mRNA levels of MMP-2, MMP-23 and ADAM-12L 
were also higher in dysfunctional PTT than in FDLT (table 3). 
In contrast with the other MMPs, expression of MMP-3 mRNA 
had decreased 15-fold in both dysfunctional PTT and FDLT 
compared with normal PTT, but there was no signiﬁ  cant differ-
ence between dysfunctional PTT and FDLT (table 3; ﬁ  gure 3C).
mRNA expression of the three major ADAMTS (a disin-
tegrin and metalloproteinase with thrombospondin domain) 
aggrecanases showed smaller changes than the other metal-
loproteinases, and each ADAMTS mRNA showed a different 
pattern (table 3). ADAMTS-5 mRNA levels were lower in both 
dysfunctional PTT and FDLT than in normal PTT (ﬁ  gure 2E). 
ADAMTS-1 mRNA levels in dysfunctional PTT were lower 
than in FDLT, although neither of these groups showed a sig-
niﬁ   cant difference from normal PTT (ﬁ   gure 2F). ADAMTS-4 
mRNA showed no substantial difference between the three ten-
don groups, although a small increase (20%) in median values in 
dysfunctional PTT compared with the paired FDLT samples was 
statistically signiﬁ  cant (table 3).
Analysis of PTT and FDLT from male patients
The male samples also showed signiﬁ  cant biochemical and 
mRNA differences between clinical groups: (A) fourfold 
higher levels of GAG in dysfunctional PTT than in FDLT 
(p<0.05); (B) more than twofold higher levels of pentosidine 
in FDLT than in dysfunctional PTT (p=0.01); (C) lower levels 
of OHPyr cross-links in FDLT than in either normal or dys-
functional PTT (p=0.05 and p=0.01 respectively); (D) higher 
levels of HHL and HLNL cross-links in FDLT than in either 
normal or dysfunctional PTT (p≤0.01 in each comparison); (E) 
higher expression of mRNA encoding types I and III collagen, 
Figure 2  Expression of mRNA in female posterior tibialis tendon (PTT) and ﬂ  exor digitorum longus tendon (FDLT). Tendon RNA samples were 
analysed for speciﬁ  c mRNA, expressed relative to 18S rRNA as outlined in the text. Each point represents an individual sample. nd (y-axis) indicates 
that the mRNA was not detectable (below 2×10−9 relative to 18S) in one or more samples. The median values are shown (horizontal bar). ***p<0.001, 
**p<0.01, *p<0.05, for differences between the indicated clinical groups. ADAMTS, a disintegrin and metalloproteinase with thrombospondin 
domain; MMP, matrix metalloproteinase; N, normal; St II, stage II.
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aggrecan, biglycan, versican and MMP-2 mRNA in dysfunc-
tional PTT compared with normal PTT and/or FDLT (ﬁ  gure 
3A,B and data not shown).
Each of these differences in the male sample set was similar 
to that observed in female patients, and there were no signiﬁ  -
cant differences between men and women in total collagen, 
total GAG, collagen modiﬁ  cations and most mRNA, in any of 
the three clinical groups (data not shown and ﬁ  gure 3). Indeed, 
combining the male and female datasets for many parameters 
increased the statistical signiﬁ  cance of the differences observed 
between clinical groups, compared with the female data alone, 
irrespective of whether the male data analysed separately 
showed signiﬁ  cant changes. However, certain mRNA differ-
ences were observed between men and women. Levels of type 
I collagen mRNA in dysfunctional PTT and type III collagen 
mRNA in FDLT were lower in men than in women, although 
this did not affect the pattern of higher expression in dysfunc-
tional PTT than in the other clinical groups (ﬁ  gure 3A). In con-
trast, MMP-3 mRNA was expressed at higher levels in both 
dysfunctional PTT and FDLT in men compared with women 
(ﬁ  gure 3C), and there were no differences between the clinical 
groups for men (ﬁ  gure 3C), in contrast with the marked differ-
ences observed in women (ﬁ  gure 3C).
DISCUSSION
Differences in matrix composition and cross-link content are 
found between functionally distinct tendons, and at different 
sites within tendons. Many of these changes reﬂ  ect different 
patterns of loading and matrix turnover, although the relation-
ship to the tendon material properties is uncertain.10 11 13 The 
PTT is a load-bearing tendon, and the normal specimens in this 
study were obtained from the region that wrapped around the 
medial malleolus, and were therefore exposed to some com-
pression, at least on the inner surface.21 The FDLT is predomi-
nantly a ‘positional’ tendon, normally not heavily loaded, and 
the specimens used in this study were obtained from a slip 
close to the bone insertion which received predominantly ten-
sile loading. Although the normal PTT and FDLT specimens 
were taken from patients with lower limb conditions, so that 
effects of reduced mobility on their phenotype cannot be 
excluded (see Methods), both groups showed normal morpho-
logical and histological appearance (table 1). Furthermore, the 
increase in pentosidine content with age in normal PTT and 
FDLT (ﬁ  gure 1) is similar to that previously reported in biceps 
brachii and patellar tendons,10–12 indicating that each of these 
tendons has a stable and long-lived matrix structure in which 
advanced glycation end products on collagen (and other long-
lived proteins) can accumulate linearly with time.
Although many parameters in the normal PTT and FDLT 
were similar (tables 2 and 3), there were some marked differ-
ences between them. The FDLT contained lower levels of the 
ketoimine-derived mature cross-link OHPyr than normal PTT 
and higher levels of the aldimine-derived mature cross-links HHL 
and HLNL (table 2 and ﬁ  gure 1). Aldimine-derived cross-links 
are generally more abundant in tendons, whereas ketoimine-
derived cross-links are typically higher in bone and cartilage.26 
OHPyr is more abundant in weight-bearing and highly stressed 
tendons,13 such as the supraspinatus tendon in the rotator cuff, 
which is subjected to compressive loads in addition to tension.10 
The cross-link proﬁ  le of FDLT is broadly similar to other posi-
tional tendons, whereas the higher OHPyr content of normal 
PTT suggests (by analogy with other tendons)10 13 adaptation 
to compression against the medial malleolus. The FDLT also 
contained lower levels of GAG and of ADAMTS-5 mRNA than 
Figure 3  Comparison of mRNA expression in female (closed circle) 
and male (open circle) posterior tibialis tendon (PTT) and ﬂ  exor 
digitorum longus tendon (FDLT). Tendon RNA samples were analysed 
for speciﬁ  c mRNA, expressed relative to 18S rRNA as outlined in the 
text. Each point represents an individual sample. The median values 
are shown (horizontal bar). Signiﬁ  cant differences between clinical 
groups for female patients are indicated fffp<0.001, ffp<0.01, and 
for male patients are indicated mp<0.05. Signiﬁ  cant differences 
between females and males of the same clinical group are indicated 
**p<0.01, *p<0.05. MMP, matrix metalloproteinase; N, normal; 
St II, stage II.
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since the main substrates of these enzymes in tendon are as 
yet unknown. The expression of MMP-3 mRNA was one of 
the few parameters to show differences between men and 
women: lower in dysfunctional PTT (and FDLT) in women 
but not in men (ﬁ  gure 3C). Whether this gender difference in 
MMP-3 expression is relevant to the higher incidence of PTT 
dysfunction in women requires further investigation; previ-
ous studies have shown a reduction in MMP-3 expression in 
Achilles tendinopathy (in men).19 34 Studies on the potential 
function(s) of MMP-23 have shown some correlation with 
endochondral ossiﬁ  cation and the ability to bind and inhibit 
potassium channels.35 36 ADAM-12 is linked to tumorigenesis, 
myogenesis and adipogenesis, and appears to have multiple 
roles in the processing of growth factors and their receptors.37 
Thus both enzymes may be associated with the changes in cell 
phenotype found in tendinopathy, although ADAM-12 expres-
sion is, unusually, increased in ruptured tendons as well as in 
tendinopathy.19  38 As with other metalloproteinases, consid-
eration must also be given to the extensive post-translational 
regulation of these enzymes by highly controlled processes of 
pro-enzyme activation and subsequent inhibition by Tissue 
Inhibitor of Metalloproteinases and other inhibitors in the tis-
sue.39 40 Further studies are required to determine whether these 
enzymes are proteolytically active in chronic tendinopathy.
Stage II PTT dysfunction and painful Achilles tendinopathy 
have different clinical presentations: although both involve 
swelling and pain, PTT dysfunction presents with deformity 
and ﬂ  attening of the foot, whereas deformity is not a clini-
cal problem in Achilles tendinopathy. It is therefore interest-
ing that the gene expression pattern in stage II PTT is in many 
respects similar to that observed in Achilles tendinopathy.17 19 
In contrast, ruptured Achilles tendons showed substantially 
different changes in enzyme and matrix gene expression,17 19 
which may be the consequence and not the cause of the rup-
ture. The molecular differences are consistent with the histo-
logical observations (see table 1) that showed similar features in 
stage II PTT to those observed in painful Achilles tendinopathy, 
and very different from the typical histology of ruptured ten-
dons.16 19 41 Increased expression of MMP-2, MMP-13, collagen 
and aggrecan and decreased MMP-3 have also been reported 
in torn rotator cuff tendons.42–45 However, these are often full-
thickness tears that also show decreased expression of decorin 
and increased MMP-9,43–45 more similar to ruptured Achilles 
tendons.17 19 Taken together, the data suggest that the underly-
ing processes in the chronic Achilles and PTT conditions are 
the same; the presentational differences may simply reﬂ  ect the 
different functions of the two musculotendinous structures: 
maintenance of the foot arch versus push-off during gait. A dif-
ference in biomechanical stability, rather than tendon structure, 
may also underlie the greater susceptibility of women to PTT 
dysfunction, since many of the biomolecular parameters appear 
similar in men and women.
In summary, the ‘stretching out’ of the PTT is accompanied 
by a process of chronic matrix remodelling, which may be indic-
ative of an incomplete healing response to repeated micro-injury 
or ‘overuse’. Treatment strategies designed to resolve or enhance 
the chronic remodelling response are likely to prove beneﬁ  cial in 
both Achilles and posterior tibialis tendinopathy.
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normal PTT (tables 1 and 2), indicating a different proteoglycan 
composition in the FDLT, possibly requiring lower maintenance 
turnover than the normal PTT. The fact that the FDLT is used 
successfully to replace dysfunctional PTT may indicate either 
that the tendon rapidly adapts to its new location, changing the 
synthesis of matrix components, or these differences in compo-
sition do not signiﬁ  cantly affect the material properties of the 
tendon.
Both the biochemical and mRNA expression changes described 
here for stage II dysfunctional PTT can be compared with previ-
ous work in other tendons. The lower than expected pentosidine 
levels in specimens from dysfunctional PTT (ﬁ  gure 1) are similar 
to those observed in degenerate supraspinatus tendons10 18 and 
Achilles tendinopathy.27 The reduction in pentosidine/collagen 
may result from reversal of the modiﬁ  cation, removal of old 
(modiﬁ  ed) collagen, or insertion of new (unmodiﬁ  ed) collagen. 
In supraspinatus tendons, replacement of the original collagen 
matrix was additionally supported by measurement of the race-
misation of aspartate, a marker of protein residence time.10 18 
In dysfunctional PTT, synthesis of new collagen matrix is indi-
cated by the observed increase in levels of mRNA encoding 
both types I and III collagens (table 3) and by increased levels of 
both types III and V collagen proteins.23 Furthermore, increased 
removal of old collagen is likely, given the increased expression 
of mRNA encoding the matrix-degrading enzymes MMP-2 (72 
kDa gelatinase) and MMP-13 (collagenase 3), which were also 
elevated in Achilles tendinopathy.19 Both these enzymes have 
activity against a variety of potential substrates, including the 
main structural component of tendon, ﬁ  brillar type I collagen. 
Taken together, our data indicate that there is a chronic remod-
elling of the original collagen matrix.
The higher GAG content in dysfunctional PTT is a common 
observation in chronic tendinopathy,16 23 28 and has been asso-
ciated with increased deposition of proteoglycans including 
aggrecan and biglycan.29 Indeed, the median ratio of aggrecan 
mRNA/versican mRNA increased from 0.37 in normal PTT to 
1.83 in dysfunctional PTT, which is very similar to the increase 
observed in chronic Achilles tendinopathy.17 These changes in 
proteoglycan expression may indicate a process of ﬁ  brocarti-
laginous change induced by forces of shear and/or compression 
acting on the tenocytes, and a switch in cell phenotype from 
tenocyte to chondrocyte. However, expression of type II col-
lagen mRNA in dysfunctional PTT remained 100- to 1000-fold 
lower than that of type I and type III (data not shown), which 
suggests only a partial phenotypic change. Alternatively, the 
increased production of aggrecan and biglycan may be second-
ary to injury or part of the chronic remodelling response, poten-
tially stimulated by the activity of cytokines and growth factors 
such as transforming growth factor β.30
In addition to increased aggrecan and biglycan expression, 
the increased proteoglycan content observed in dysfunctional 
PTT may result in part from a decrease in ADAMTS-5 mRNA 
expression (table 2). The proteolytic processing of proteo-
glycans in tendons is evidently a normal process in healthy 
tendon,31  32 and recent evidence from ADAMTS-5−/− mice 
indicates that ADAMTS-5 aggrecanase activity is required for 
the maintenance of normal tendon structure and some biome-
chanical properties.33 Both the FDLT and Achilles tendons in 
the ADAMTS-5−/− mice showed increased aggrecan deposi-
tion, but the biomechanical changes observed differed between 
the two tendons.33
The functional signiﬁ   cance of decreased expression of 
MMP-3 mRNA and increased expression of MMP-23 and 
ADAM-12 mRNA in dysfunctional PTT is hard to interpret, 
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